Participants were randomised to : insulin glargine with up to one insulin glulisine injection ( G + 1 ) ; insulin glargine with stepwise addition of up to three insulin glulisine injections ( G + 3 ) ; or twice-daily premixed 70/30 insulin protamine-aspart/aspart ( PM-2 ) .